David Matuskey, MD
DownloadHi-Res Photo
Cards
Appointments
Psychiatry
Secondary
Titles
Director, NeuroPET Imaging Program, Radiology and Biomedical Imaging; Medical Director, Yale Positron Emission Tomography (PET) Center
Contact Info
Appointments
Psychiatry
Secondary
Titles
Director, NeuroPET Imaging Program, Radiology and Biomedical Imaging; Medical Director, Yale Positron Emission Tomography (PET) Center
Contact Info
Appointments
Psychiatry
Secondary
Titles
Director, NeuroPET Imaging Program, Radiology and Biomedical Imaging; Medical Director, Yale Positron Emission Tomography (PET) Center
Contact Info
About
Titles
Associate Professor of Radiology and Biomedical Imaging
Director, NeuroPET Imaging Program, Radiology and Biomedical Imaging; Medical Director, Yale Positron Emission Tomography (PET) CenterBiography
I am a board certified psychiatrist and neuropsychiatrist with research work that has been translational in nature and focused on elucidating the underlying pathology of brain conditions such as Autism Spectrum Disorder, substance abuse and neuropsychiatric disorders (e.g., Parkinson's disease) with an aim to find effective clinical treatments guided by molecular neuroimaging. Studies have included using in vivo PET imaging to investigate the role of neuroreceptors such as dopamine D3, serotonin 1B and 6, MGlur5 and kappa opioid systems, neuroinflammation, and most recently, synaptic density (SV2A) in clinical and nonclinical populations. Ongoing interests include imaging neuropsychiatric and addictive disorders and the demographic, social and environmental factors influencing our brain.
Appointments
Radiology & Biomedical Imaging
Associate Professor on TermPrimaryPsychiatry
Associate Professor on TermSecondaryNeurology
Assistant ProfessorSecondaryNeurology
Associate Professor on TermSecondary
Other Departments & Organizations
- Bioimaging Sciences
- Center for Brain & Mind Health
- Connecticut Mental Health Center
- Mental Health PET Radioligand Development (MHPRD) Program
- Movement Disorders
- Neurology
- NeuroPET Imaging Program
- Positron Emission Tomography (PET)
- Psychiatric Symptoms in Neurology Research Program
- Psychiatry
- Radiology & Biomedical Imaging
- Yale Cocaine Research Clinic
Education & Training
- Clinical Neuroscience Research Fellow
- Yale University (2010)
- Senior Resident
- Yale University (2009)
- Resident
- University of Connecticut (2008)
- MD
- St Matthew's University School of Medicine (2005)
- BA
- University of South Florida, Psychology (1998)
- BS
- University of South Florida, Biology (1998)
Research
Overview
Medical Subject Headings (MeSH)
Addiction Medicine; Autistic Disorder; Essential Tremor; Frontotemporal Dementia; Meditation; Mental Disorders; Molecular Imaging; Neuroimaging; Neuropsychiatry; Parkinson Disease; Social Class
ORCID
0000-0001-7508-6572
Research at a Glance
Yale Co-Authors
Frequent collaborators of David Matuskey's published research.
Publications Timeline
A big-picture view of David Matuskey's research output by year.
Research Interests
Research topics David Matuskey is interested in exploring.
Nabeel Nabulsi, PhD
Richard Carson, PhD
Jean-Dominique Gallezot, PhD
Irina Esterlis, PhD
Kelly Cosgrove, PhD
Yiyun Huang, PhD
74Publications
2,585Citations
Neuroimaging
Mental Disorders
Molecular Imaging
Social Class
Publications
Performance Characteristics of the NeuroEXPLORER, a Next-Generation Human Brain PET/CT Imager
Li H, Badawi R, Cherry S, Fontaine K, He L, Henry S, Hillmer A, Hu L, Khattar N, Leung E, Li T, Li Y, Liu C, Liu P, Lu Z, Majewski S, Matuskey D, Morris E, Mulnix T, Omidvari N, Samanta S, Selfridge A, Sun X, Toyonaga T, Volpi T, Zeng T, Jones T, Qi J, Carson R. Performance Characteristics of the NeuroEXPLORER, a Next-Generation Human Brain PET/CT Imager. Journal Of Nuclear Medicine 2024, jnumed.124.267767. PMID: 38871391, DOI: 10.2967/jnumed.124.267767.Peer-Reviewed Original ResearchAltmetricConceptsPeak noise-equivalent count rateNoise-equivalent count rateTime-of-flight resolutionField of viewCount rateExtended axial field-of-viewTransverse field-of-viewAxial field-of-viewField-of-view centerMini-Derenzo phantomSpatial resolutionTangential spatial resolutionsCount rate performanceContrast recovery coefficientHuman brain PET imagingMeasurements of spatial resolutionNEMA sensitivityEnergy resolutionScatter fractionBrain phantomBackprojection reconstructionBrain PET imagingTime resolutionRadial offsetF-FDG imagingTreatment resistant depression in a young female successfully treated with a combination of ketamine and pramipexole – A case report
Ibrahim W, Yang Y, Matuskey D. Treatment resistant depression in a young female successfully treated with a combination of ketamine and pramipexole – A case report. Psychiatry Research Case Reports 2024, 3: 100228. DOI: 10.1016/j.psycr.2024.100228.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionForced swim testResistant depressionAntidepressant medicationAdequate trial of antidepressant medicationClasses of antidepressant medicationsTrials of antidepressant medicationsMesolimbic dopaminergic pathwayPatients' depressive symptomsD2/3 receptorsSwim testMood stabilizersDopaminergic pathwaysElectroconvulsive therapyDepressive symptomsAdequate trialKetamine infusionDopamine deficiencyFailure of treatmentDepressionYoung adult femalesPramipexoleCase reportPreclinical studiesKetamineA review of the kappa opioid receptor system in opioid use
Cayir S, Zhornitsky S, Barzegary A, Sotomayor-Carreño E, Sarfo-Ansah W, Funaro M, Matuskey D, Angarita G. A review of the kappa opioid receptor system in opioid use. Neuroscience & Biobehavioral Reviews 2024, 162: 105713. PMID: 38733895, DOI: 10.1016/j.neubiorev.2024.105713.Peer-Reviewed Original ResearchAltmetricConceptsKappa opioid receptor systemKappa-opioid receptorsOUD subjectsKappa-opioid receptor expressionOpioid withdrawal symptomsWithdrawal symptomsDynorphin levelsPeripheral blood lymphocytesOpioid useDrug-seeking/taking behaviorAnti-reward systemsKappa-opioid receptor antagonistClinical studiesCerebrospinal fluidOpioid receptor systemKOR/dynorphin systemDisorder subjectsOpioid receptorsOpioid intoxicationBlood lymphocytesReceptor systemOpioidWeb of ScienceClinical roleDynorphin37. The Structural Connectome Constrains in Vivo Synaptic Density Loss in Schizophrenia
Chopra S, Worhunsky P, Naganawa M, Angarita G, Cosgrove K, D'Souza D, Matuskey D, Nabulsi N, Huang Y, Carson R, Esterlis I, Skosnik P, Holmes A, Radhakrishnan R. 37. The Structural Connectome Constrains in Vivo Synaptic Density Loss in Schizophrenia. Biological Psychiatry 2024, 95: s90. DOI: 10.1016/j.biopsych.2024.02.215.Peer-Reviewed Original ResearchTranslational PET Imaging of HDAC6 Using 18F-Bavarostat in PTSD
Bonomi R, Girgenti M, Naganawa M, Matuskey D, Cosgrove K. Translational PET Imaging of HDAC6 Using 18F-Bavarostat in PTSD. Biological Psychiatry 2024, 95: s40-s41. DOI: 10.1016/j.biopsych.2024.02.102.Peer-Reviewed Original ResearchRelationship between neuroimaging and cognition in frontotemporal dementia: An FDG‐PET and structural MRI study
Cayir S, Volpi T, Toyonaga T, Gallezot J, Yang Y, Sadabad F, Mulnix T, Mecca A, Fesharaki‐Zadeh A, Matuskey D. Relationship between neuroimaging and cognition in frontotemporal dementia: An FDG‐PET and structural MRI study. Journal Of Neuroimaging 2024 PMID: 38676301, DOI: 10.1111/jon.13206.Peer-Reviewed Original ResearchAltmetricConceptsMoCA scoresFDG-PETAssociation of cognitionStandardized uptake value ratioMontreal Cognitive AssessmentSignificant positive associationFrontotemporal dementiaPrimary outcome measurePosterior cingulate cortexDecline of cognitive functionYears of ageGM volumeFrontal cortexOutcome measuresCognitive dysfunctionGray matterCognitive AssessmentMoCAAssociated with cognitive dysfunctionFluorodeoxyglucose (FDG)-PETPositive associationMagnetic resonance imagingPartial volume correctionCognitive functionDementiaInvestigating Metabotropic Glutamate Receptor 5 (mGluR5) in Autism Spectrum Disorder with [18F]FPEB PET Imaging (S8.007)
Sadabad F, Yang Y, Gravel P, Naples A, Torres K, Nabulsi N, Ropchan J, Huang Y, Hillmer A, Esterlis I, Carson R, Mcpartland J, Matuskey D. Investigating Metabotropic Glutamate Receptor 5 (mGluR5) in Autism Spectrum Disorder with [18F]FPEB PET Imaging (S8.007). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000206171.Peer-Reviewed Original ResearchMeasuring Synaptic Density and Dopamine Transporter Availability in Parkinson's Disease: A PET Imaging Study with 11C-UCB-J and 18F-FE-PE2I (P7-3.007)
Saadabad F, Volpi T, Honhar P, Naganawa M, Cayir S, Tinaz S, Gallezot J, angarita G, Holmes S, Carson R, Finnema S, Matuskey D. Measuring Synaptic Density and Dopamine Transporter Availability in Parkinson's Disease: A PET Imaging Study with 11C-UCB-J and 18F-FE-PE2I (P7-3.007). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205367.Peer-Reviewed Original ResearchInvestigating the Relationships of Atrophy and Hypometabolism on Cognitive Decline in Frontotemporal Dementia (P1-9.018)
Cayir S, Yang Y, Volpi T, Sadabad F, Toyonaga T, Gallezot J, Mecca A, Fesharaki-Zadeh A, Matuskey D. Investigating the Relationships of Atrophy and Hypometabolism on Cognitive Decline in Frontotemporal Dementia (P1-9.018). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204352.Peer-Reviewed Original ResearchConceptsDoes seasonal variation affect the neuroimmune system? A retrospective [11C]PBR28 PET study in healthy individuals
Ibrahim W, An J, Yang Y, Cosgrove K, Matuskey D. Does seasonal variation affect the neuroimmune system? A retrospective [11C]PBR28 PET study in healthy individuals. Neuroscience Letters 2024, 828: 137766. PMID: 38583505, PMCID: PMC11073647, DOI: 10.1016/j.neulet.2024.137766.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsTranslocator protein levelsPositron emission tomographyNeuroimmune systemHealthy individualsHuman studiesPositron emission tomography scanTranslocator proteinTest-retest variabilityBrain TSPO levelsVolume of distributionPositron emission tomography imagingBrain regionsCentral nervous systemTranslocator protein expressionGene polymorphismsCell markersHealthy subjectsTSPO levelsInterindividual variabilityNeuropsychiatric disordersEmission tomographyPET studiesNervous systemMonthsNo significant effect
Clinical Trials
Current Trials
Brain Connections & HIV Status
HIC ID2000033582RoleSub InvestigatorPrimary Completion Date12/31/2027Recruiting ParticipantsGenderBothAge18 years - 80 yearsMeditation and Synaptic Density
HIC ID2000030601RolePrincipal InvestigatorPrimary Completion Date08/31/2024Recruiting ParticipantsGenderBothAge28 years - 70 yearsStudy of Safety and of the Mechanism of BLZ945 in ALS Patients
HIC ID2000026495RoleSub InvestigatorPrimary Completion Date04/05/2022Recruiting ParticipantsGenderBothAge18 years - 75 yearsM1 Schizophrenia PET Study
HIC ID2000031171RoleSub InvestigatorPrimary Completion Date04/30/2023Recruiting ParticipantsGenderBothAge18 years - 55 yearsKetamine for the Treatment of Depression in Parkinson's Disease
HIC ID2000030394RoleSub InvestigatorPrimary Completion Date08/31/2024Recruiting ParticipantsGenderBothAge40 years - 70 years
Academic Achievements and Community Involvement
honor NARSAD Young Investigator Award
National AwardBrain & Behavior Research FoundationDetails08/07/2018United Stateshonor Michael Kuhar Travel Award
International AwardInternational Drug and Alcohol Research SocietyDetails08/23/2011United Stateshonor NIDA-ISAM Travel Fellowship
International AwardNIDA-ISAMDetails01/01/2011United Stateshonor NARSAD Young Investigator Award
National AwardBrain & Behavior Research FoundationDetails08/01/2010United States
Links & Media
News
- January 29, 2023
Symposium Highlights Importance of Biomedical Imaging for Understanding Neurological Disease
- November 15, 2022Source: Biological Psychiatry
Yale Study Seeks to Understand Neurobiology Underlying Bipolar Disorder Vs. Major Depressive Disorder
- November 15, 2021
Michael J. Fox Foundation Grant Will Fund First Clinical Trial of Ketamine to Treat Depression in People With Parkinson’s Disease
- November 20, 2019
Yale Researchers Measure Ketamine's Effects on a Glutamate Receptor
Get In Touch
Contacts
Academic Office Number
Locations
801 Howard Avenue
Academic Office
New Haven, CT 06519